A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2 million to TwinStrand Biosciences and the University of Washington, cementing a November 2023 jury verdict that found Guardant willfully infringed on two Duplex Sequencing patents.
Financial Penalty
The penalty covers willful infringement across 11 products and services that generated roughly 90% of Guardant Health’s revenue during the period. The total award includes an initial $83.4 million jury verdict through mid-2023, $19.5 million in post-trial damages through early 2024, $119.4 million from a 6% court-ordered royalty rate through May 2026, and $22.9 million in calculated interest.
Future Royalties And Validity Assured
Moving forward, the court mandates that Guardant Health submit quarterly accounting reports and pay an ongoing 6% royalty on the contested products until the patents officially expire in March 2033.
Any unpaid judgment balances will also continue accruing interest. Earlier in the litigation process, the judge rejected all counterclaims and dismissed the defense’s attempts to secure a new trial.
The final legal order explicitly upheld the validity of the two disputed patents. While separate administrative reviews remain active at the U.S. Patent and Trademark Office, neither patent is currently under review for invalidation.
GH Stock Price Activity: Guardant Health shares were down 3.29% at $165.07 at the time of publication on Monday,
according to Benzinga Pro data.
Photo by Tada Images via Shutterstock
Recent Comments